SKI O 703

Drug Profile

SKI O 703

Alternative Names: mesylate salt of SKI-O-592; SKI-O-703

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Oscotec
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase I Idiopathic thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Sep 2016 Phase-I clinical trials in Idiopathic thrombocytopenic purpura in USA (PO) before September 2016
  • 02 Sep 2016 Phase-I clinical trials in Systemic lupus erythematosus in USA (PO) before September 2016
  • 19 Apr 2016 SKI O 703 is available for licensing as of 19 Apr 2016. http://eng.kddf.org/Tasks/?mode=view&TaskId=102&p=1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top